Vimarsana
Biggest News Aggregation in the World

Max Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Max Therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Max Therapeutics Today - Breaking & Trending Today

Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery - Vimarsana News

Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery

Published: May 5, 2023

/PRNewswire/ -- Formosa Pharmaceuticals, Inc. (6838.TWO) and AimMax Therapeutics, Inc. (United States) announce the submission of a New Drug Application to the...

Source: prnewswire.com
Related Topics:
United StatesT Ai PeiFormosa Pharmaceuticals IncUnited States Food Drug AdministrationFormosa PharmaceuticalsAimmax Therapeutics IncAimmax TherapeuticsNew Drug ApplicationUnited States FoodDrug AdministrationMax TherapeuticsFormosa Pharmaceuticals Inc
Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-302 for the Treatment of Inflammation and Pain after Cataract Surgery. - Vimarsana News

Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-302 for the Treatment of Inflammation and Pain after Cataract Surgery.

Published: August 9, 2022

/PRNewswire/ -- Formosa Pharmaceuticals, Inc. (6838.TWO) and AimMax Therapeutics, Inc. (United States) report successful top-line results from CPN-302, the...

Source: prnewswire.com
Related Topics:
T Ai PeiUnited StatesDerek NunezLaurene WangFormosa PharmaAimmax Therapeutics IncFormosa Pharmaceuticals IncMerick CoFormosa PharmaceuticalsPrnewswire Formosa Pharmaceuticals IncAimmax TherapeuticsAimmax Therapeutic Chief Medical OfficerAimmax Therapeutic Chief Executive OfficerFormosa Pharmaceutical Chief ExecutiveFormosa PharmaceuticalMax TherapeuticsFormosa Pharmaceuticals Inc
Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery - Vimarsana News

Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery

Published: May 12, 2022

/PRNewswire/ -- Formosa Pharmaceuticals, Inc. (TWO.6838) and AimMax Therapeutics, Inc. (United States) report successful top-line results from CPN-301, the...

Source: prnewswire.com
Related Topics:
United StatesNorth CarolinaResearch Triangle ParkAimmax Therapeutics IncFormosa PharmaceuticalsAimmax TherapeuticsMax TherapeuticsFormosa Pharmaceuticals Inc
Formosa Pharmaceuticals and AimMax Therapeutics to Present Phase 2 Trials Results of APP13007 for the Treatment after Cataract Surgery at ARVO 2022 Annual Meeting - Vimarsana News

Formosa Pharmaceuticals and AimMax Therapeutics to Present Phase 2 Trials Results of APP13007 for the Treatment after Cataract Surgery at ARVO 2022 Annual Meeting

Published: April 28, 2022

/PRNewswire/ -- Formosa Pharmaceuticals, Inc. (TWO.6838) and Aimmax Therapeutics, Inc. (United States) announced that results from a Phase 2 clinical study of...

Source: prnewswire.com
Related Topics:
United StatesNorth CarolinaResearch Triangle ParkJeffrey LevensonAimmax Therapeutics IncFormosa Pharmaceuticals IncFormosa PharmaceuticalsClobetasol Propionate Ophthalmic NanosuspensionCataract SurgeryFormosa PharmaceuticalAimmax TherapeuticsMax TherapeuticsPharmaceuticals IncFormosa Pharmaceuticals Inc
Formosa Pharmaceuticals and AimMax Therapeutics to Present Phase 2 Trials Results of APP13007 for the Treatment after Cataract Surgery at ARVO 2022 Annual Meeting - Vimarsana News

Formosa Pharmaceuticals and AimMax Therapeutics to Present Phase 2 Trials Results of APP13007 for the Treatment after Cataract Surgery at ARVO 2022 Annual Meeting

Published: April 28, 2022

/PRNewswire/ -- Formosa Pharmaceuticals, Inc. (TWO.6838) and Aimmax Therapeutics, Inc. (United States) announced that results from a Phase 2 clinical study of...

Source: prnewswire.com
Related Topics:
United StatesNorth CarolinaResearch Triangle ParkJeffrey LevensonAimmax Therapeutics IncFormosa Pharmaceuticals IncFormosa PharmaceuticalsClobetasol Propionate Ophthalmic NanosuspensionCataract SurgeryFormosa PharmaceuticalAimmax TherapeuticsMax TherapeuticsPharmaceuticals Inc